Full GALILEO results: Why did rivaroxaban fail after TAVR?

The full results of the prematurely terminated GALILEO trial confirm that oral anticoagulation with rivaroxaban was associated with worse clinical outcomes compared with antiplatelet therapy in patients after successful transcatheter aortic valve replacement (TAVR). However, the GALILEO-4D CT sub-study showed that rivaroxaban prevents some leaflet thickening and leaflet motion, indicative of a specific benefit. Both studies were simultaneously published in the New England Journal of Medicine [1,2]. Prof. George Dangas (Icahn School of Medicine at Mount Sinai, USA) pointed out that although current guidelines recommend dual antiplatelet therapy after TAVR, the evidence base for the optimal treatment strategy for patients who have had TAVR is weak [3]. Earlier observ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 26 February, 202024 February, 2021